Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of MIM-D3 in Dry Eye
NCT01257607Phase 2Completed
- Sponsor
- Mimetogen Pharmaceuticals
- Start
- Nov 2010
- Primary completion
- May 2011
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of tavilermide in dry eye syndrome (DED), sponsored by Mimetogen Pharmaceuticals. Started Nov 2010; status: completed.
02
Drugs
tavilermide
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT01257607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01257607.